Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-11-05
2000-08-08
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514212, 514397, 540603, 546210, 5483147, A61K 31445, C07D40106
Patent
active
061002798
ABSTRACT:
Disclosed are compounds of Formula I ##STR1## or pharmaceutically acceptable salts or solvates thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula I. Further disclosed is a method of treating allergy (for example asthma), inflammation, hypotension, raised intraocular pressure (such as glaucoma)--i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimer's, schizophrenia, obesity and migraine) comprising administering an effective amount of a compound of Formula I to a patient in need of such treatment. Also disclosed are methods for treatment of upper airway allergic responses comprising administering a compound, or salt or solvate thereof, of formula I in combination or admixture with a histamine H, receptor antagonist.
REFERENCES:
patent: 5463074 (1995-10-01), Shih et al.
patent: 5559113 (1996-09-01), Schwartz et al.
patent: 5578616 (1996-11-01), Aslanian et al.
patent: 5708171 (1998-01-01), Schwartz et al.
patent: 5807872 (1998-09-01), Shih et al.
patent: 5869479 (1999-02-01), Kreutner et al.
Leurs et al. "The histamine H3 receptor . . . " progree in Drug Res. V. 39, p. 139, 1992.
Schunack et al. "Benzhydryl ethers possessing combined histamine H3/H1 receptor antagonist activity" BIOSIS 10782164, 1996.
Snyman et al. "Influence of histamine receptor antagonists . . . " MEDLINE 07777637, 1993.
Aslanian Robert G.
Piwinski John J.
Rosenblum Stuart B.
Solomon Daniel M.
Vaccaro Wayne D.
Chang Ceila
Jeanette Henry C.
Schering Corporation
LandOfFree
Imidazoylalkyl substituted with a five, six or seven membered he does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazoylalkyl substituted with a five, six or seven membered he, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazoylalkyl substituted with a five, six or seven membered he will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1150523